WO2008139152A1 - Composés pharmaceutiques contenant un n-oxyde - Google Patents

Composés pharmaceutiques contenant un n-oxyde Download PDF

Info

Publication number
WO2008139152A1
WO2008139152A1 PCT/GB2008/001595 GB2008001595W WO2008139152A1 WO 2008139152 A1 WO2008139152 A1 WO 2008139152A1 GB 2008001595 W GB2008001595 W GB 2008001595W WO 2008139152 A1 WO2008139152 A1 WO 2008139152A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
oxide
group
phenyl
activity
Prior art date
Application number
PCT/GB2008/001595
Other languages
English (en)
Inventor
Robert George Boyle
Stuart Travers
Original Assignee
Sentinel Oncology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709150A external-priority patent/GB0709150D0/en
Priority claimed from GB0724379A external-priority patent/GB0724379D0/en
Application filed by Sentinel Oncology Limited filed Critical Sentinel Oncology Limited
Publication of WO2008139152A1 publication Critical patent/WO2008139152A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Definitions

  • This invention relates to therapeutically useful compounds having reduced hERG affinity and to methods for diminishing HERG affinity. More particularly, the invention provides compounds that have been modified in order to remove unwanted hERG potassium channel activity while at the same time, retaining their desired pharmacological activity.
  • the cardiac ion channel (hERG channel) encoded by the human ether-a-go-go-related gene (hERG) is one of a family of potassium ion channels the first member of which was identified in the late 1980s in a mutant Drosophila me/anogasterfruitfly (see Jan, L.Y. and Jan, Y.N. (1990). A Superfamily of Ion Channels. Nature, 345 (6277): 672).
  • the biophysical properties of the hERG potassium ion channel are described in Sanguinetti, M. C, Jiang, C, Curran, M. E., and Keating, M. T. (1995).
  • hERG encodes the lkr potassium channel.
  • HERG a Human Inward Rectifier in the Voltage- Gated Potassium Channel Family. Science, 269:92-95.
  • the initial phase of depolarization in cardiac muscle tissue (phase 0) is mediated primarily by the activation of voltage-dependent Na+ channels.
  • Na+ channel activity is also the main determinant of ventricular depolarization as represented by the QRS wave of the ECG.
  • the shape of the remainder of the action potential including the initial repolarization phase (phasel), the plateau phase (phase 2), and the later phases of repolarization (phases 3 and 4), results from the flow of Ca2+ into the cell through voltage-dependent Ca2+ channels, balanced by the efflux of K+ out of the cell through voltage-dependent K+ channels.
  • the activity of these channels also helps to determine the QT interval measured on the ECG.
  • K+ channels exist in the human ventricular myocardium each carrying a distinct K+ current (/).
  • the HERG K+ channel carries the delayed rectifier current known as /Kr. Inhibition of HERG channel activity can lead to a prolongation of the action potential duration and the QT interval.
  • Cisapride Gl stimulant Disopyramide Anti-arrhythmic
  • hERG blocking activity and therapeutically useful effects such as kinase inhibition, GPCR agonism or antagonism and therapeutically useful ion channel blockade is currently considered to be of substantial importance in the development of any new drug.
  • therapeutically useful effects such as kinase inhibition, GPCR agonism or antagonism and therapeutically useful ion channel blockade is currently considered to be of substantial importance in the development of any new drug.
  • An object of the present invention is to provide a means for the removal of hERG activity in compounds which have been shown to bind at the hERG ion channel whilst not eliminating or reducing substantially the pharmacological activity of the compound..
  • the invention provides a method of modifying a drug compound known to have deleterious hERG activity, wherein the drug compound contains a basic tertiary amino group; which method comprises reacting the drug compound with an oxidising agent to form an N-oxide at the said basic tertiary amino group so as to give an N-oxide drug compound, whereby the N-oxide drug compound has reduced hERG activity relative to its parent non-N-oxide drug compound.
  • the N-oxide drug compound has a hERG inhibitory activity which is at least ten fold less than the hERG inhibitory activity of the non-N-oxide drug compound, and more preferably is at least twenty fold less active, and most preferably is at least thirty fold less active than the non-N-oxide drug compound.
  • the invention provides a method of preparing a therapeutically active compound having reduced hERG activity, which method comprises:
  • the invention provides a method of preparing a therapeutically active compound having reduced hERG activity, which method comprises:
  • the nitrogen atom of the basic tertiary amino group does not form part of an aromatic ring; i.e. the N-oxide is not formed at a nitrogen atom of a heteroaryl group such as a pyridine, pyrimidine or pyrazine ring.
  • the nitrogen atom can form part of a cyclic non-aromatic amine group such as the nitrogen atom in an N-substituted pyrrolidine or piperidine group.
  • the basic tertiary amino group can form part of an acylic amine function.
  • the basic tertiary amino group is preferably a non-aromatic amino group; i.e. it is not attached to an aromatic ring (e.g. as in the case of an aniline or aminopyridine).
  • drug compound refers to a compound that has a therapeutic use.
  • the term does not cover compounds that have no therapeutic use.
  • the therapeutic use may be any one of a wide range of uses, and examples include antibiotic, anti-arrhythmic, anti-nausea, anti-psychotic, anti-malarial, anti-anginal and anti-cancer uses.
  • the therapeutic use may be one which has been demonstrated through clinical studies in patients or one which is predictable on the basis of in vivo studies carried out in animals, or studies comprising cell based assays or in vitro assays for activity against a biological target such as an enzyme or a receptor.
  • therapeutically active compound refers to a compound that has an actual or potential therapeutic use and which displays biological activity that either demonstrates a therapeutic use or is indicative of a therapeutic use.
  • the biological activity can be activity which has been demonstrated through clinical studies in patients or can be activity in one or more in vivo or in vitro assays that is predictive of therapeutic utility.
  • the therapeutically active compound may act as a modulator (e.g. inhibitor) of an enzyme such as a kinase or may act as an agonist or antagonist at a receptor, where such modulatory or agonist or antagonist activity is indicative of a therapeutic use.
  • the therapeutic use or biological activity of the N-oxide drug compound or therapeutically active compound may be of the same type as the therapeutic use or biological activity of the non-N-oxide compound, or the N-oxide compound may have a different therapeutic use or biological activity to the non-N-oxide compound.
  • the N-oxide drug compound or therapeutically active compound typically contains the structural fragment A:
  • the nitrogen atom of the N-oxide is attached to three methylene
  • the N-oxide drug compound or therapeutically active compound contains the structural fragment (C):
  • n 1 , 2 or 3.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a a pharmaceutically acceptable carrier and an N-oxide drug compound or therapeutically active compound containing structural fragment (A) 1 (B) or (C) as defined herein.
  • the N-oxide drug compound or therapeutically active compound may be other than:
  • the drug compound or therapeutically active compound may also be other than a compound as disclosed in our earlier applications GB 0611565.3 and PCT/GB2007/002123, the contents of each of which are incorporated herein by reference.
  • the N-oxide drug compound or therapeutically active compound may be other than a compound of formula W 1 -NH-C(O)-NH-W 2 where W 1 and W 2 are the same or different and each is an optionally substituted aryl or optionally substituted heteroaryl group.
  • the N-oxide drug compound or therapeutically active compound may be other than a compound of the formula (X):
  • G is CH 2 , O, NH, NHCO or CONH;
  • A is a group (CH 2 ) n where n is 1 to 4 provided that when G is O or NH, n is at least 2;
  • X 1 is nitrogen or CH
  • X 2 is nitrogen or a group CR 5 ;
  • X 3 is nitrogen or a group CR 5 ;
  • X 4 is nitrogen or CH; provided that no more than two of X 2 , X 3 and X 4 are nitrogen;
  • R 1 is hydrogen, cyano, C 1-4 alkyl, trifluoromethyl or a 5-6 membered monocyclic aryl or heteroaryl group containing up to 3 heteroatom ring members selected from O, N and
  • R 2 is hydrogen, cyano, C 1-4 alkyl, trifluoromethyl or a 5-6 membered monocyclic aryl or heteroaryl group containing up to 3 heteroatom ring members selected from O, N and
  • R 1 and R 2 are optionally substituted by one or two C 1-4 alkyl groups; provided that no more than one of R 1 and R 2 can be an aryl or heteroaryl group; or R 1 and R 2 together with the carbon atoms to which they are attached form a benzene ring; R 3 and R 4 are the same or different and each is Ci -4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, piperidine, piperazine, M-methylpiperazine or morpholine group; or R 3 together with the nitrogen atom to which it is attached and the moiety A together form a saturated 5 to 7 membered heterocyclic ring optionally containing a second heteroatom ring member selected from O and S, wherein the heterocyclic ring is optionally substituted by 1 to 4 methyl groups, and R 4 is C 1-4 alkyl;
  • R 5 is hydrogen or a substituent R 6 ;
  • R 6 is halogen; hydroxy; trifluoromethyl; cyano; nitro; amino; mono- or di-C 1-4 hydrocarbylamino; a carbocyclic or heterocyclic group having from 3 to 12 ring members and optionally substituted by one or more substituents R 7 ; or a group R a -R b ;
  • R a is a bond, O, CO, X 1 C(X 2 ), C(X 2 )X 1 , X 1 C(X 2 )X 1 , S, SO, SO 2 , NR C , SO 2 NR 0 or NR 0 SO 2 ;
  • R b is: • hydrogen;
  • a C 1-12 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di- C 1-8 non-aromatic hydrocarbylamino; and carbocyclic and heterocyclic groups having from 3 to 12 ring members optionally substituted by one or more substituents R 7 ; wherein one or more carbon atoms of the C 1-12 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR 0 , X 1 C(X 2 ), C(X 2 )X 1 or X 1 C(X 2 JX 1 ; R° is R b , hydrogen or C 1-4 hydrocarbyl;
  • R 8 is selected from R 6 except that any carbocyclic or heterocyclic groups constituting or forming part of R 8 may not bear a substituent containing or consisting of a carbocyclic or heterocyclic group but may optionally bear one or more substituents selected from halogen; hydroxy; trifluoromethyl; cyano; nitro; amino; mono- or di-C 1-4 hydrocarbylamino; or a group R a -R bb ; where R a is as hereinbefore defined and R bb is hydrogen or a C 1-6 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C 1-4 saturated hydrocarbylamino and wherein one or more carbon atoms of the C 1-6 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR C , X 1 C(X 2 ), C(X 2 )X
  • the compound (or N-oxide drug compound) may also be other than a compound selected from;
  • the invention provides a compound of the formula (1):
  • R 1 is hydrogen, hydroxy, C 1-4 alkoxy or together with R 2 forms a second bond between the two carbon atoms marked "q";
  • R 2 is hydrogen, hydroxy, C 1-4 alkoxy or together with R 1 forms a second bond between the two carbon atoms marked "q";
  • Q 1 is a bond, NR 3 or C(O)NR 3 or NR 3 CO;
  • R 3 is hydrogen or Ci -4 alkyl
  • Ar 1 is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members of which up to four ring members are heteroatoms selected from O, N and S, the monocyclic or bicyclic aryl or heteroaryl group being optionally substituted by one or more substituents selected from a group R 10 consisting of halogen, hydroxy, amino, mono-or di- C 1-4 alkylamino, C 1-4 acylamino, C 1-4 alkoxy, oxo, trifluoromethyl, difluoromethoxy, cyano, phenyl, benzyl, benzoyl, halobenzyl, halobenzoyl, C 1-4 alkylsulphonyl, C 1-4 alkylsulphinyl, C 1-4 alkylsulphanyl, alkylsulphonylamino, C 1-4 acyl, C 1-4 alkoxycarbonyl, and carb
  • Ar 1 is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members of which up to four ring members are heteroatoms selected from O, N and S. Preferably up to two ring members are heteroatoms selected from O, N and S. More Preferably, Ar 1 is an optionally substituted phenyl group or an optionally substituted benzimidazole or 1 ,3-dihydrobenzimidazol-2-one group.
  • the optional substituents for Ar 1 are preferably selected from a group R 1Oa consisting of fluorine, chlorine, bromine, methoxy, amino, fluorobenzyl (e.g. 4-fluorobenzyl), mono-or di-methylamino, acetylamino, oxo, trifluoromethyl, difluoromethoxy, cyano, methylsulphonyl, acetyl, methoxycarbonyl and ethoxycarbonyl.
  • fluorobenzyl e.g. 4-fluorobenzyl
  • mono-or di-methylamino acetylamino, oxo
  • trifluoromethyl difluoromethoxy
  • cyano methylsulphonyl
  • acetyl methoxycarbonyl and ethoxycarbonyl.
  • the optional substituents for Ar 1 are preferably selected from a group R 10b consisting of chlorine, methoxy, amino, fluorobenzyl (e.g. 4-fluorobenzyl) and oxo.
  • R 1 is hydrogen, hydroxy, C 1-4 alkoxy or together with R 2 forms a second bond between the two carbon atoms marked "q". More preferably, R 1 is hydrogen, hydroxy, or together with R 2 forms a second bond between the two carbon atoms marked "q". In one embodiment, R 1 is hydrogen.
  • R 1 is hydroxy
  • R 1 together with R 2 forms a second bond between the two carbon atoms marked "q".
  • R 2 is hydrogen, hydroxy, Ci -4 alkoxy or together with R 1 forms a second bond between the two carbon atoms marked "q". More preferably, R 2 is hydrogen, methoxy or together with R 1 forms a second bond between the two carbon atoms marked "q".
  • R 2 is hydrogen
  • R 2 is methoxy
  • the moiety Q 1 is a bond, NR 3 , C(O)NR 3 or NR 3 CO.
  • Q 1 is a bond, NH, C(O)NH or NHCO.
  • Q 1 is a bond
  • Q 1 is NH
  • Q 1 is C(O)NH.
  • Q 1 is NHCO.
  • n is 2.
  • n 3.
  • the moiety Q 2 is a bond, O, S, SO, SO 2 , NR 3 , CO or CH(Ar 3 ).
  • Q 2 is a bond, O, CO or CH(Ar 3 ).
  • Q 2 is a bond
  • Q 2 is O. In another embodiment, Q 2 is CO.
  • Q 2 is CH(Ar 3 ).
  • Ar 3 is a monocyclic aryl or heteroaryl group of 5 or 6 ring members of which up to two ring members are heteroatoms selected from O, N and S, the aryl or heteroaryl group being optionally substituted by one or more substituents R 10 .
  • Ar 3 is a phenyl group optionally substituted by one to three (e.g. O, 1 or 2) substituents R 10 .
  • Ar 3 is a phenyl group substituted by one or two halogen atoms selected from fluorine and chlorine.
  • Ar 2 is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members of which up to four ring members are heteroatoms selected from O, N and S, the monocyclic or bicyclic aryl or heteroaryl group being optionally substituted by one or more substituents R 10 .
  • Ar 2 is a monocyclic aryl or heteroaryl group of 5 or 6 ring members of which up to two (and more preferably up to one) ring members are heteroatoms selected from O, N and S, or a bicyclic heteroaryl group of 9 ring members of which one or two ring members are nitrogen atoms, the monocyclic and bicyclic groups being optionally substituted by one or more substituents R 10 .
  • Ar 2 is a phenyl group or a benzimidazolyl or 1 ,3-dihydrobenzimidazol- 2-one group optionally substituted by one or more substituents R 1Oc wherein R 1Oc is selected from fluorine, chlorine, bromine, methoxy, amino, fluorobenzyl (e.g. 4- fluorobenzyl), mono-or di-methylamino, acetylamino, oxo, trifluoromethyl, difluoromethoxy, cyano, methylsulphonyl, methylsulphonylamino, acetyl, methoxycarbonyl and ethoxycarbonyl.
  • R 1Oc is selected from fluorine, chlorine, bromine, methoxy, amino, fluorobenzyl (e.g. 4- fluorobenzyl), mono-or di-methylamino, acetylamino, oxo, trifluoromethyl, difluoromethoxy
  • Ar 2 is a phenyl group optionally substituted by one to three substituents R 1Od selected from fluorine, chlorine, amino and methoxy.
  • Ar 2 is a 1,3-dihydrobenzimidazol-2-one group group.
  • the compound of formula (1) may be other than; 4-amino-5-chloro-N- ⁇ (3R,4S)-1-[3-(4-fluoro-phenoxy)-propyl]-3-methoxy-1-oxy- piperidin-4-yl ⁇ -2-methoxy-benzamide; and
  • the invention also provides a compound of the formula (2):
  • R 4 is hydrogen or methyl
  • R 5 is hydrogen or methyl
  • R 6 is hydrogen, methyl or C 1-4 alkoxymethyl; or R 4 together with R 5 and the intervening nitrogen and carbon atoms forms a pyrrolidine or piperidine ring; or R 5 together with R 6 and the intervening nitrogen and carbon atoms forms a piperidine ring;
  • R 7 is hydrogen, C 1-8 alkyl, or an optionally substituted benzyl group wherein the optional substituents for the benzyl group are selected from a group R 10 consisting of halogen, hydroxy, amino, mono-or di- C 1-4 alkylamino, C 1-4 acylamino, C 1-4 alkoxy, oxo, trifluoromethyl, difluoromethoxy, cyano, phenyl, benzyl, benzoyl, halobenzyl, halobenzoyl, C 1-4 alkylsulphonyl, C 1-4 alkylsulphinyl, C 1-4 alkylsulphanyl, alkylsulphonylamino, C 1-4 acyl, C 1-4 alkoxycarbonyl, and carboxy;
  • R 8 is hydrogen or C 1-4 alkyl; or the moiety
  • R 9 is hydrogen, hydroxy or C 1-4 alkyl;
  • Q 3 is a bond, O or CH 2 or is selected from: - CH(OH);
  • R 11 is hydrogen, Ci -4 alkyl or a benzyl group wherein the aromatic ring of the benzyl group is optionally substituted with 1 to 3 substituents R 10 ;
  • q is O or 1 provided that when q is O, Q 3 is other than O; and
  • Ar 4 is selected from: ⁇ quinolinyl (e.g. 4-quinolinyl) optionally substituted with 1 to 3 substituents R 10 ;
  • phenothiazinyl e.g. 10-phenothiazinyl
  • R 10 substituents
  • ⁇ phenanthrenyl optionally substituted with 1 to 3 substituents R 10 ; ⁇ phenyl optionally substituted with 1 to 3 substituents R 10 ;
  • R 12 is a group:
  • R 13 is a group:
  • R 14 is a group:
  • R 4 is hydrogen or methyl
  • R 5 is hydrogen or methyl
  • R 6 is hydrogen, methyl or Ci -4 alkoxymethyl.
  • R 6 is hydrogen, methyl or 2-methylpropyloxymethyl.
  • R 6 is hydrogen
  • R 6 is methyl
  • R 6 is 2-methylpropyloxymethyl.
  • R 4 together with R 5 and the intervening nitrogen and carbon atoms forms a pyrrolidine or piperidine ring.
  • R 4 together with R 5 and the intervening nitrogen and carbon atoms forms a pyrrolidine ring.
  • R 7 is hydrogen, C 1-8 alkyl, or an optionally substituted benzyl group wherein the optional substituents for the benzyl group are selected from a group R 10.
  • R 7 is hydrogen or Ci -8 alkyl.
  • moiety R 7 an optionally substituted benzyl group wherein the optional substituents for the benzyl group are selected from a group R 10 .
  • the optional substituents for the benzyl group are more typically selected from a group R 1Oc as hereinbefore defined. More preferably, the benzyl group is substituted by a methylsulphonylamino group, for example at the 4-position of the benzene ring thereof.
  • R 8 is hydrogen or Ci -4 alkyl. In one embodiment, R 8 is hydrogen. In another embodiment, R 8 is C 1-4 alkyl such as methyl.
  • q can be 0 or 1. In one embodiment, q is 1. In another embodiment, q is 0.
  • R 9 is hydrogen, hydroxy or C 1-4 alkyl.
  • R 9 is hydrogen
  • R 9 is hydroxy
  • R 9 is C 1-4 alkyl, e.g. methyl.
  • ⁇ Q 3 is CH 2 CH(OH).
  • Q 3 is HNC(O). • Q 3 is C(O)NH. - Q 3 is CH 2 CH(CH 3 )NH.
  • ⁇ Q 3 is C(CONH 2 )(phenyl) wherein the phenyl group is optionally substituted with 1 to 3 substituents R 10 .
  • ⁇ Q 3 is C(1-acetoxypropyl)(phenyl) wherein the phenyl group is optionally substituted with 1 to 3 substituents R 10 .
  • ⁇ Q 3 is N(R 11 ) where R 11 is hydrogen, C 1-4 alkyl or a benzyl group wherein the aromatic ring of the benzyl group is optionally substituted with 1 to 3 substituents R 10 .
  • the substituents R 10 may be selected from any of the groups R 1Oa , R 10b and R 1Oc as defined herein. In one embodiment, however, p is 0; i.e. the phenyl ring is unsubstituted.
  • r is 0, 1 , 2 or 3.
  • the substituents R 10 may be selected from any of the groups R 1Oa , R 10b and R 1Oc as defined herein. In one embodiment, however, r is 0; i.e. the phenyl ring is unsubstituted.
  • Q 3 is N(R 11 )
  • R 11 is hydrogen, C 1-4 alkyl or a benzyl group wherein the aromatic ring of the benzyl group is optionally substituted with 1 to 3 substituents R 10 .
  • R 11 is hydrogen, or a benzyl group wherein the aromatic ring of the benzyl group is optionally substituted with 1 to 3 substituents R 10 , R 1Oa , R 10b and R 1Oc as defined herein.
  • R 11 is hydrogen.
  • R 11 is an unsubstituted benzyl group.
  • ⁇ Ar 4 is quinolinyl (e.g. 4-quinolinyl) optionally substituted with 1 to 3 substituents R 10 .
  • ⁇ Ar 4 is pyridyl optionally substituted with 1 to 3 substituents R 10 .
  • Ar 4 is phenothiazinyl (e.g. 10-phenothiazinyl) optionally substituted with 1 to 3 substituents R 10 .
  • Ar 4 is phenanthrenyl optionally substituted with 1 to 3 substituents R 10 .
  • Ar 4 is phenyl optionally substituted with 1 to 3 substituents R 10 .
  • Ar 4 is phenyl substituted with R 12 and optionally with 0 to 2 further substituents
  • Ar 4 is indolyl (e.g. 1-indolyl) substituted by a group R 13 .
  • pyridyl e.g. 4-pyridyl substituted by a group R 14 .
  • R 12 is a group:
  • R 13 is a group:
  • the asterisk indicates the point of attachment to the pyridyl ring, e.g. the 3- position of the pyridyl ring.
  • the group Ar 4 is optionally substituted by 1 to 3 substituents R 10 .
  • the substituents R 10 may be as defined above or may be chosen from any of groups R ioa R iob and R ioc as defjned herein.
  • substituents R 10 consists of fluorine, chlorine, bromine, iodine, trifluoromethyl, methoxy, methylthio, methylsulphonyl, amino and methylsulphonylamino.
  • Another compound of the invention is the compound (4):
  • the various functional groups and substituents making up the compounds of the formulae (1), (2) and (3) are typically chosen such that the molecular weight of the compound of the formula (I) does not exceed 1000. More usually, the molecular weight of the compound will be less than 750, for example less than 700, or less than 650, or less than 600, or less than 550. More preferably, the molecular weight is less than 525 and, for example, is 500 or less.
  • the compound of the invention containing a fragment A, B or C as defined above may be an N-oxide (formed at a non-aromatic basic tertiary amino group) of any one or more compounds selected from acecainide, aceperone, acepromazine, acetophenazine, acranil, adiphenine, ahistan, ajmaline, alfentanil, allylprodine, almitrine, alverine, aminopentamide, aminopromazine, amisulpride, amodiaquin, amorolfine, amoxapine, amperozide, anileride, apocodeine, apomorphine, aripiprazole, atevirdine, azaperone, azatadine, azelastine, bamifylline, bamipine, barndipine, benactyzine, bencyclane, benidipine, benperidol, ben
  • a reference to a compound of the formulae (1) and (2) and sub-groups thereof also includes ionic forms, salts, solvates, isomers, tautomers, prodrugs, isotopes and protected forms thereof, for example, as discussed below.
  • the salts can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
  • Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
  • acid addition salts include salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g. L- ascorbic), L-aspartic, benzenesulphonic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulphonic, (+)-(1 S)-camphor-10-sulphonic, capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulphuric, ethane-1 ,2-disulphonic, ethanesulphonic, 2-hydroxyethanesulphonic, formic, fumaric, galactaric, gentisic, glucoheptonic, D-gluconic, glucuronic (e.g.
  • D-glucuronic glutamic (e.g. L-glutamic), ⁇ - oxoglutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isethionic, (+)-L- lactic, ( ⁇ )-DL-lactic, lactobionic, maleic, malic, (-)-L-malic, malonic, ( ⁇ )-DL-mandelic, methanesulphonic, naphthalene-2-sulphonic, naphthalene-1 ,5-disulphonic, 1-hydroxy- 2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulphuric, tannic, (+)-L-tartaric, thiocyan
  • a salt may be formed with a suitable cation.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
  • suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
  • Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 J 4 + .
  • the salt forms of the compounds of the invention are typically pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. ScL, Vol. 66, pp. 1- 19. However, salts that are not pharmaceutically acceptable may also be prepared as intermediate forms which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in the purification or separation of the compounds of the invention, also form part of the invention.
  • tautomeric forms include, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
  • keto enol enolate as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
  • references to compounds of the formulae (1) and (2) include all optical isomeric forms thereof (e.g. enantiomers, epimers and diastereoisomers), either as individual optical isomers, or mixtures (e.g. racemic mixtures) or two or more optical isomers, unless the context requires otherwise.
  • optical isomers may be characterised and identified by their optical activity (i.e. as + and - isomers, or d and / isomers) or they may be characterised in terms of their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, lngold and Prelog, see Advanced Organic Chemistry by Jerry March, 4 th Edition, John Wiley & Sons, New York, 1992, pages 109-114, and see also Cahn, lngold & Prelog, Angew. Chem. Int. Ed. Engl., 1966, 5, 385-415.
  • Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support) and such techniques are well known to the person skilled in the art.
  • optical isomers can be separated by forming diastereoisomeric salts with chiral acids such as (+)-tartaric acid, (-)- pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (- )-camphorsulphonic, separating the diastereoisomers by preferential crystallisation, and then dissociating the salts to give the individual enantiomer of the free base.
  • chiral acids such as (+)-tartaric acid, (-)- pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (- )-camphorsulphonic
  • compositions containing a compound of the formula (I) having one or more chiral centres wherein at least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the compound of the formula (I) is present as a single optical isomer (e.g.
  • 99% or more (e.g. substantially all) of the total amount of the compound of the formula (I) may be present as a single optical isomer (e.g. enantiomer or diastereoisomer).
  • the compounds of the invention include compounds with one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
  • a reference to hydrogen includes within its scope 1 H, 2 H (D), and 3 H (T).
  • references to carbon and oxygen include within their scope respectively 12 C, 13 C and 14 C and 16 O and 18 O.
  • the isotopes may be radioactive or non-radioactive.
  • the compounds contain no radioactive isotopes. Such compounds are preferred for therapeutic use.
  • the compound may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in a diagnostic context.
  • formula (I) Also encompassed by formula (I) are any polymorphic forms of the compounds, solvates (e.g. hydrates), complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals) of the compounds, and pro-drugs of the compounds.
  • solvates e.g. hydrates
  • complexes e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals
  • pro-drugs is meant for example any compound that is converted in vivo into a biologically active compound of the formula (I).
  • N-oxide drug compounds of the invention have a wide range or different therapeutic uses including for example anti-biotic, anti-arrhythmic, anti-nausea, antipsychotic, anti-histamine, anti-anginal and anti-cancer uses.
  • N-oxide drug compounds of the invention have sustantially lower hERG activity than their corresponding non-N-oxide analogues.
  • Preferred N-oxide drug compounds of the invention are those that have at least a tenfold lower hERG channel inhibiting ativity than their corresponding non-N-oxide forms.
  • the hERG channel inhibiting activity of the compounds can be determined using the method of Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT. Biophys J. 1998 Jan;74(1):230-41 , as described in more detail below.
  • the N-oxide drug compounds of the invention can be prepared by the oxidation of the corresponding non-N-oxide compounds.
  • the N-oxide drug compounds of formulae (1), (2), (3) and (4) can be prepared by the N-oxidation of compounds of the formulae (10), (11), (9) and (8) respectively:
  • the N-oxidation may be carried out using an oxidising agent that selectively or preferentially oxidises non-aromatic nitrogen atoms.
  • reagents capable of oxidizing a non-aromatic amine to an N-oxide in the presence of a basic heteroaromatic nitrogen atom are arylsulphonyloxaziridines such as 2-benzenesulphonyl-3-phenyl-oxaziridine which has the structure (12):
  • 2-Benzenesulphonyl-3-phenyl-oxaziridine can be prepared by the methods set out in the examples.
  • the compound of formula (8) is known by the code number VX-680 and is described in the articles by (1) Elizabeth A Harrington et al., Nature Medicine 10, 262 - 267 (2004); and (2) Farid Gizatullin et al., Cancer Res. 2006 Aug 1 ;66 (15):7668-77 16885368.
  • the compound can be made using the methods described in WO 02/068415 or methods analogous thereto.
  • Amiodarone and analogues thereof can be prepared by the methods described in US 3248401 or methods analogous thereto.
  • Bepridil and analogues thereof can be prepared by the methods described in US 3962238, DE 2310918 or methods analogous thereto.
  • Chloroquine and analogues thereof can be prepared by the methods described in US 2233970 or methods analogous thereto.
  • Cisapride and analogues thereof can be prepared by the methods described in US 4962115, EP 76530 or methods analogous thereto.
  • Disopyramide and analogues thereof can be prepared by the methods described in US 225054 or methods analogous thereto.
  • Dofetilide and analogues thereof can be prepared by the methods described in US 4959366, EP 245997 or methods analogous thereto.
  • Domperidone and analogues thereof can be prepared by the methods described in US 4066772 or methods analogous thereto.
  • Droperidol and analogues thereof can be prepared by the methods described in US 3161645 or methods analogous thereto.
  • Halofantrine and analogues thereof can be prepared by the methods described in US 4507288, EP 138374 or methods analogous thereto.
  • Haloperidol and analogues thereof can be prepared by the methods described in US 3438991 , GB 895309 or methods analogous thereto.
  • lbutilide and analogues thereof can be prepared by the methods described in US 5155268, EP 164865 or methods analogous thereto.
  • Levomethadyl and analogues thereof can be prepared by the methods described in A. Pohland et al, J. Amer. Chem. Soc, 71, 460, (1949) or methods analogous thereto.
  • Mesoridazine and analogues thereof can be prepared by the methods described in US 3084161 or methods analogous thereto.
  • Methadone and analogues thereof can be prepared by the methods described in US 2644010, US 2983757 or methods analogous thereto.
  • Pimozide and analogues thereof can be prepared by the methods described in FR M3695 or methods analogous thereto.
  • Procainamide and analogues thereof can be prepared by the methods described in M. Yamazaki et al, J. Pharm Soc. Jap., 73, 294 (1953) and Y. Tashika et al, ibid, 1069 or methods analogous thereto.
  • Sotalol and analogues thereof can be prepared by the methods described in Uloth et al., J. Med. Chem., 9, 88 (1966) or methods analogous thereto.
  • Thioridazine and analogues thereof can be prepared by the methods described in Bourquin et al, HeIv. Chim. Acta, 41, 1072 (1958) or methods analogous thereto.
  • the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound of the invention together with a pharmaceutically acceptable carrier, and optionally one or more additional excipients.
  • a pharmaceutical composition e.g. formulation
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the formula (I) and a pharmaceutically acceptable carrier.
  • compositions can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration.
  • compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery.
  • the delivery can be by bolus injection, short term infusion or longer term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, co-solvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels, lyophilisation protectants and combinations of agents for, inter alia, stabilising the active ingredient in a soluble form and rendering the formulation isotonic with the blood of the intended recipient.
  • aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, co-solvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels,
  • compositions for parenteral administration may also take the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents (R. G. Strickly, Solubilizing Excipients in oral and injectable formulations, Pharmaceutical Research, VoI 21(2) 2004, p 201-230).
  • a drug molecule that is ionizable can be solubilized to the desired concentration by pH adjustment if the drug's pK a is sufficiently away from the formulation pH value.
  • the acceptable range is pH 2-12 for intravenous and intramuscular administration, but subcutaneously the range is pH 2.7-9.0.
  • the solution pH is controlled by either the salt form of the drug, strong acids/bases such as hydrochloric acid or sodium hydroxide, or by solutions of buffers which include but are not limited to buffering solutions formed from glycine, citrate, acetate, maleate, succinate, histidine, phosphate, tris(hydroxymethyl)-aminomethane (TRIS), or carbonate.
  • the combination of an aqueous solution and a water-soluble organic solvent/surfactant is often used in injectable formulations.
  • the water- soluble organic solvents and surfactants used in injectable formulations include but are not limited to propylene glycol, ethanol, polyethylene glycol 300, polyethylene glycol 400, glycerin, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP; Pharmasolve), dimethylsulphoxide (DMSO), Solutol HS 15, Cremophor EL, Cremophor RH 60, and polysorbate 80.
  • Such formulations can usually be, but are not always, diluted prior to injection.
  • Propylene glycol, PEG 300, ethanol, Cremophor EL, Cremophor RH 60, and polysorbate 80 are the entirely organic water-miscible solvents and surfactants used in commercially available injectable formulations and can be used in combinations with each other.
  • the resulting organic formulations are usually diluted at least 2-fold prior to IV bolus or IV infusion.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • the pharmaceutical formulation can be prepared by lyophilising a compound of Formula (I) or acid addition salt thereof. Lyophilisation refers to the procedure of freeze-drying a composition. Freeze-drying and lyophilisation are therefore used herein as synonyms. A typical process is to solubilise the compound and the resulting formulation is clarified, sterile filtered and aseptically transferred to containers appropriate for lyophilisation (e.g. vials).
  • vials they are partially stoppered with lyo-stoppers.
  • the formulation can be cooled to freezing and subjected to lyophilisation under standard conditions and then hermetically capped forming a stable, dry lyophile formulation.
  • the composition will typically have a low residual water content, e.g. less than 5% e.g. less than 1% by weight based on weight of the lyophile.
  • the lyophilisation formulation may contain other excipients for example, thickening agents, dispersing agents, buffers, antioxidants, preservatives, and tonicity adjusters.
  • Typical buffers include phosphate, acetate, citrate and glycine.
  • antioxidants include ascorbic acid, sodium bisulphite, sodium metabisulphite, monothioglycerol, thiourea, butylated hydroxytoluene, butylated hydroxyl anisole, and ethylenediaminetetraacetic acid salts.
  • Preservatives may include benzoic acid and its salts, sorbic acid and its salts, alkyl esters of para-hydroxybenzoic acid, phenol, chlorobutanol, benzyl alcohol, thimerosal, benzalkonium chloride and cetylpyridinium chloride.
  • the buffers mentioned previously, as well as dextrose and sodium chloride, can be used for tonicity adjustment if necessary.
  • Bulking agents are generally used in lyophilisation technology for facilitating the process and/or providing bulk and/or mechanical integrity to the lyophilized cake.
  • Bulking agent means a freely water soluble, solid particulate diluent that when co- lyophilised with the compound or salt thereof, provides a physically stable lyophilized cake, a more optimal freeze-drying process and rapid and complete reconstitution.
  • the bulking agent may also be utilised to make the solution isotonic.
  • the water-soluble bulking agent can be any of the pharmaceutically acceptable inert solid materials typically used for lyophilisation.
  • Such bulking agents include, for example, sugars such as glucose, maltose, sucrose, and lactose; polyalcohols such as sorbitol or mannitol; amino acids such as glycine; polymers such as polyvinylpyrrolidine; and polysaccharides such as dextran.
  • the ratio of the weight of the bulking agent to the weight of active compound is typically within the range from about 1 to about 5, for example of about 1 to about 3, e.g. in the range of about 1 to 2.
  • dosage forms may be via filtration or by autoclaving of the vials and their contents at appropriate stages of the formulation process.
  • the supplied formulation may require further dilution or preparation before delivery for example dilution into suitable sterile infusion packs.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • the pharmaceutical composition is in a form suitable for i.v. administration, for example by injection or infusion.
  • the pharmaceutical composition is in a form suitable for sub-cutaneous (s.c.) administration.
  • Pharmaceutical dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches and buccal patches.
  • compositions containing compounds of the formula (I) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
  • tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, eg; lactose, sucrose, sorbitol or mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch. Tablets may also contain such standard ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g.
  • swellable crosslinked polymers such as crosslinked carboxymethylcellulose
  • lubricating agents e.g. stearates
  • preservatives e.g. parabens
  • antioxidants e.g. BHT
  • buffering agents for example phosphate or citrate buffers
  • effervescent agents such as citrate/bicarbonate mixtures.
  • Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form.
  • Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.
  • the solid dosage forms can be coated or un-coated, but typically have a coating, for example a protective film coating (e.g. a wax or varnish) or a release controlling coating.
  • a protective film coating e.g. a wax or varnish
  • the coating e.g. a Eudragit TM type polymer
  • the coating can be designed to release the active component at a desired location within the gastro- intestinal tract.
  • the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively release the compound in the stomach or in the ileum or duodenum.
  • the drug can be presented in a solid matrix comprising a release controlling agent, for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract.
  • a release controlling agent for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract.
  • the matrix material or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract.
  • the active compound can be formulated in a delivery system that provides osmotic control of the release of the compound. Osmotic release and other delayed release or sustained release formulations may be prepared in accordance with methods well known to those skilled in the art.
  • compositions for topical use include ointments, creams, sprays, patches, gels, liquid drops and inserts (for example intraocular inserts). Such compositions can be formulated in accordance with known methods.
  • compositions for parenteral administration are typically presented as sterile aqueous or oily solutions or fine suspensions, or may be provided in finely divided sterile powder form for making up extemporaneously with sterile water for injection.
  • formulations for rectal or intra-vaginal administration include pessaries and suppositories which may be, for example, formed from a shaped moldable or waxy material containing the active compound.
  • compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administrated in standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known.
  • the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose.
  • a formulation may contain from 1 nanogram to 2 grams of active ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient.
  • particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).
  • a unit dosage form may contain from 1 milligram to 2 grams, more typically 10 milligrams to 1 gram, for example 50 milligrams to 1 gram, e.g. 100 miligrams to 1 gram, of active compound.
  • the active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic.
  • the benzene- sulphonamide (2 g) was taken together with benzaldehyde (1.34 g), Amberlyst resin (0.2 g) and molecular sieves (2 g) in dry toluene (20 ml) and refluxed (110° C) for 30 minutes (till evolution of water ceases).
  • the reaction mixture cooled to RT (without stirring) filtered through a Celite® bed and washed with toluene (40 ml).
  • N-Benzylidene-benzenesulphonamide was taken together with a saturated solution of sodium bicarbonate (12.5 ml) and N-benzyl-N,N-diethylethanaminium chloride (0.25 g) and cooled to 0° C.
  • 3-Chloroperbenzoic acid (3 g) in chloroform (22.5 ml) was added dropwise to the reaction mixture over a period of 15 min at 0° C and stirring maintained for 1 hour.
  • the organic layer was separated and washed with water (20 ml), 10% Na 2 SO 3 solution (20 ml), sat. NaHCO 3 (20 ml) and sat. NaCI (20 ml).
  • N-[4-(2- ⁇ [2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino ⁇ -ethoxy)-phenyl]- methanesulfonamide (115 mg) was dissolved in 3 ml dry DCM and 1.1 eq of 2- benzenesulphonyl-3-phenyl-oxaziridine was added at room temperature. The reaction mixture was stirred for overnight. The precipitate was filtered and washed with DCM and dried to yield the title compound.
  • the title compound was prepared from commercially available 3-(indol-3-yl)-4-[1-(N- dimethylaminopropyl)-indol-3-yl]-maleimide by following the method of Example 1.
  • Examples A to E are presented as comparative examples. In these examples, which are specifically excluded from formulae (1) and (2) herein, the formation of an N-oxide at the tertiary amino nitrogen atom has been found to have a deleterious effect on biological activity that is not compensated for by the reduced hERG activity.
  • the title compound was prepared from commercially available 4-amino-5-chloro-N- ⁇ (3R,4S)-1-[3-(4-fluoro-phenoxy)-propyl]-3-methoxy-piperidin-4-yl ⁇ -2-methoxy- benzamide by following the method of Example 1.
  • the title compound was prepared from commercially available 1- ⁇ 1-[4,4-bis-(4-fluoro- phenyl)-butyl]-piperidin-4-yl ⁇ -1 ,3-dihydro-benzoimidazol-2-one by following the method of Example 1.
  • the title compound was prepared from commercially available 1 -(4-tert-butyl-phenyl)- 4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol by following the method of Example 1.
  • the title compound was prepared from commercially available 2-(3,4-dimethoxy- phenyl)-5- ⁇ [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino ⁇ -2-isopropyl-pentanenitrile by following the method of Example 1.
  • the compounds of Examples 6 to 11 may be prepared.
  • the precursor compounds in Examples 6 to 11 can be prepared by the synthetic routes described in Bilodeau M. T., Bioorg. Med. Chem. Lett. (2004), J4, 2941-2945, the methods described in WO 01/17995 (PCT/USOO/24432) and methods analogous thereto.
  • Examples 1 to 5 were each tested for hERG inhibiting activity using the method of Zhou Z, Gong Q, Ye B 1 Fan Z, Makielski JC 1 Robertson GA, January CT. Biophys J. 1998 Jan;74(1):230-41.
  • Test compounds are tested in triplicate in a 5-point dose response curve on HEK-293 cells stably expressing the hERG potassium channel. Potassium current is measured using the patch clamp technique on a Molecular Devices Patch Express 7000. hERG channels are activated by 2 second pulses to +20 mV from a holding potential of -80 mV, and peak tail currents are recorded upon repolarization to -50 mV. This voltage- clamp pulse protocol is performed continuously during the experiment (vehicle control, test compound, washout, and positive control additions). An interpulse interval of 15 seconds allows recovery from any residual inactivation. Test compounds are incubated with cells between 3-8 minutes until the current reaches a steady state level, defined by a Standard Deviation of 0.01. After the final test compound concentration is tested, test compound is washed out with continuous perfusion of extracellular solution for 3 minutes, followed by application of positive control (10 uM Cisparide). If the positive control fails to achieve 100% inhibition the experiment is discarded.
  • positive control 10
  • Test compounds are diluted in 100% DMSO at 1000X the highest concentration to be tested, vortexed, and sonicated. Visual inspection will determine that compounds are completely solubilized. Test compounds are then diluted into glass vials in 100% DMSO for all test concentrations at 1000X the final concentration to be tested and vortexed. Test compounds are then diluted 1 :1000 into extracellular solution and vortexed to achieve final concentration for testing. Final DMSO concentration is 0.1% for all concentrations of test compounds, Vehicle (negative) control, and Cisapride (positive) control in extracellular solution.
  • the compositions of the solutions used are as follows:
  • N-oxides of the invention and their non-N-oxide precursors were tested in receptor or enzyme binding assays relevant to the biological activities of the precursor compounds and, where appropriate, IC 50 values were measured.
  • Histamine H1 receptor binding ability was determined by MDS Pharmaceutical Services by means of a GTP Y S binding assay using [ 35 S] GTP Y S, human recombinant CHO cells, and 3 ⁇ M histamine as a control. Test compounds were incubated for 30 minutes. (ii) Estrogen ⁇ receptor binding assay
  • the ability of the compounds of Example 3 to bind to estrogen receptors was measured by means of an assay using human recombinant estrogen ⁇ (ER ⁇ ) receptors expressed in Sf9 insect cells.
  • ER ⁇ estrogen ⁇
  • a 4.5 ng aliquot of the receptor proteins in modified Tris-HCI buffer pH 7.5 was incubated with 0.5 nM [ 3 H]Estradiol for 2 hours at 25 0 C in the presence or absence of test compound. Non-specific binding was estimated in the presence of 1 mM diethylstilbestrol.
  • the receptor proteins were filtered and washed and the filters were then counted to determine [3H]Estradiol specifically bound. From the results obtained, the IC 50 values of the compounds of Example 3 were determined.
  • PKC ⁇ (h) (5-10 mil) was incubated with 20 mM HEPES pH7.4, 0.03% Triton X-100, 0.1 mM, 0.1 mg/mL phosphatidylserine, 10 ⁇ g/mL diacylglycerol, 0.1 mg/mL histone H1, 10 mM MgAcetate and [ ⁇ -33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required) and either no test compound (control) or varying concentrations of test compound. The reaction was initiated by the addition of the MgATP mix.
  • the reaction was stopped by the addition of 5 ⁇ l_ of a 3% phosphoric acid solution. 10 ⁇ L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting. From the results, the IC 50 values of the test compounds were obtained.
  • VEGF endothelial growth factor
  • KDR receptor tyrosine kinase
  • HUVEC cells Human Umbilical Vein Endothelial Cells (HUVEC cells) (Lonza # CC-2519) were seeded in 96-well plates at a concentration of 5000 cells per well in complete EGM-2 endothelial media and allowed to adhere overnight. The cells were washed and the complete media was replaced with basal media containing 10ng/ml VEGF. Test compounds were prepared from 1OmM DMSO stocks to give a final concentration range from 3 ⁇ M toinM and vehicle control. The DMSO content was constant at 0.4%. Test compounds were incubated with the cells for 48h at 37°C 5% CO 2 in a humidified atmosphere. Alamar blue 10% (v/v) was then added and incubated for a further 6h, and fluorescent product detected using the BMG FLUOstar plate reader. Data were analysed using a 4-parameter logistic equation in GraphPad Prism.
  • Example 1 The compounds of Example 1 were tested for activity against Plasmodium falciparum, the parasite responsible for malaria.
  • Two strains of P. falciparum were used: (a) the 3D7 clone of NF54 isolate which is sensitive to all anti-malarials, (b) the K1 strain originating from Thailand that is resistant to chloroquine and pyrimethamine, but sensitive to mefloquine.
  • the cultures are naturally asynchronous (65-75% ring stage) and were maintained in RPMI 1640 medium supplemented with 5% washed human A+ erythrocytes, 25 rtiM Hepes, 32 nM NaHCO 3 , and 0.5% Albumax II® (lipid-rich bovine serum albumin) (Invitrogen), 0.2% w/v glucose, 0.03% L-glutamine and 150 OM cold hypoxanthine). All cultures and assays were conducted at 37°C under 5% CO2, 95% air mixture.
  • Drug sensitivity assays Assays were performed in sterile 96-well microtitre plates in assay medium (culture medium containing only 5uM cold hypoxanthine). Stock drug solutions were prepared in 100% DMSO (dimethylsulfoxide) at 20 mg/ml unless otherwise suggested by the supplier. The compound was further diluted in 96-well plates to the appropriate concentration using complete medium RPMI 1640 supplemented with 5uM cold hypoxanthine and AlbuMAXII.
  • Parasite cultures were washed three times with RPMI 1640 to remove excess cold hypoxanthine and diluted to a 0.5% parasitemia. Fifty ⁇ l of culture were added to the plates containing the drugs to give a final volume of 100 ⁇ l/well (0.5% parasitemia, 2.5% hematocrit). Each drug was tested in triplicate and parasite growth compared to control and blank (uninfected erythrocytes) wells. Plates were incubated for 24 h, at which point 20 ul (0.1-0.2 uCi/well) of [ 3 H] hypoxanthine (Perkin Elmer, Hounslow, United Kingdom) was added to each well.
  • the preliminary screen uses the 3D7 strain.
  • the compounds were usually tested at 6 concentrations (30, 10, 3, 1, 0.3, and 0.1 ⁇ g/ml) unless otherwise indicated. If the compound does not affect parasite growth at 10 ⁇ g/ml it is classified as inactive, between 10 and 1 ⁇ g/ml, the compound is designated as partially active, and if ⁇ 1 ⁇ g/ml, the compound is classified as active and is further evaluated by three-fold serial dilutions in a repeat test.
  • IC 50 was determined by a sigmoidal dose response analysis using Microsoft x/FitTM (IDBS, UK). For each assay, the IC 50 and IC 90 values for each parasite line were determined against the known anti-malarials chloroquine and artesunate, plus other standard compounds appropriate for the assay. Activity criteria: IC 50 ⁇ g/ml:
  • the KB cells were harvested, counted and washed in serum-free medium (2000 rpm, 10 mins, 4 0 C) and re-suspended in fresh medium (RPMI 1640 +10% HIFC) at a concentration of 4x10 4 /ml. 100 ⁇ l was added to wells on a 96-well plate (4x10 3 /well). The plate was incubated overnight at 37 0 C, 5%CO 2 /air mix to allow the cells to adhere.
  • serum-free medium 2000 rpm, 10 mins, 4 0 C
  • fresh medium RPMI 1640 +10% HIFC
  • test compounds were prepared in 100% DMSO 20mg/ml (with ball milling or sonicating if necessary) and diluted down to a starting concentration of 600 ⁇ g/ml (2X top concentration) with RPMI + 10% HIFCS, unless otherwise indicated.
  • the control wells have no drug.
  • a 10-fold serial dilution was performed across the plate - 300, 30, 3 etc etc.
  • Podophyllotoxin was used as the control drug.
  • the plate was incubated for 72 hours at 37 0 C, 5%CO 2 /air.
  • Example 2 the hERG activity was substantially reduced but the biological activity upon which the therapeutic activity of the compound is based is affected to a much lesser extent. In these compounds, therefore, the formation of an N-oxide is highly beneficial in a therapeutic context. Any small reduction in biological activity at a relevant target can be compensated for by small increases in concentration of the compound without increasing the hERG activity to a level at which it may cause problems.
  • Compounds of the invention in which formation of an N-oxide has been found to be particularly beneficial are compounds having kinase inhibiting activity, for example tyrosine kinase inhibiting or serine kinase inhibiting activity, and compounds having estrogen receptor binding activity.
  • Compounds having kinase inhibiting activity or estrogen receptor binding activity represent preferred embodiments of the present invention.
  • a further and most unexpected result of the formation of the N-oxide of astemazole is that it dramatically reduces the cellular toxicity of the compound as demonstrated by the relative activities of astemazole per se and astemazole N-oxide against KB cells (see Example 8).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé de préparation d'un composé thérapeutiquement actif ayant une activité hERG réduite. Ce procédé comprend les opérations consistant à : (a) sélectionner un composé médicament non N-oxyde contenant un groupe amino tertiaire basique, ledit composé non N-oxyde étant connu pour avoir ou étant soupçonné avoir un niveau thérapeutiquement inacceptable d'activité inhibitrice de hERG ; (b) tester le composé médicament non N-oxyde pour l'activité inhibitrice de hERG ; (c) amener à réagir le composé médicament non N-oxyde avec un agent oxydant pour former un composé médicament N-oxyde ayant un N-oxyde au niveau du groupe amino tertiaire basique ; (d) tester le composé médicament N-oxyde pour l'activité inhibitrice de hERG ; (e) tester le composé médicament N-oxyde pour une activité thérapeutiquement utile ; (f) comparer l'activité inhibitrice de hERG du composé médicament N-oxyde et du composé médicament non N-oxyde ; et (g) lorsque le composé médicament N-oxyde a une activité thérapeutiquement utile et a une activité hERG qui est au moins dix fois inférieure à celle de l'activité inhibitrice de hERG du composé médicament non N-oxyde, formuler le composé médicament N-oxyde pour une utilisation en médecine. L'invention porte également sur de nouveaux composés préparés par le procédé mentionné ci-dessus et sur l'utilisation des nouveaux composés en médecine.
PCT/GB2008/001595 2007-05-11 2008-05-09 Composés pharmaceutiques contenant un n-oxyde WO2008139152A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0709150.7 2007-05-11
GB0709150A GB0709150D0 (en) 2007-05-11 2007-05-11 Pharmaceutical compounds
GB0724379.3 2007-12-13
GB0724379A GB0724379D0 (en) 2007-12-13 2007-12-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
WO2008139152A1 true WO2008139152A1 (fr) 2008-11-20

Family

ID=39597835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001595 WO2008139152A1 (fr) 2007-05-11 2008-05-09 Composés pharmaceutiques contenant un n-oxyde

Country Status (1)

Country Link
WO (1) WO2008139152A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012028614A1 (fr) * 2010-09-01 2012-03-08 Janssen Pharmaceutica Nv Antagonistes de récepteur de 5-ht2b
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10159268B2 (en) 2013-02-08 2018-12-25 General Mills, Inc. Reduced sodium food products
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
CN110317198A (zh) * 2019-08-13 2019-10-11 信阳师范学院 一种吩噻嗪化合物及其制备方法和应用
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
EP3868751A1 (fr) 2015-10-02 2021-08-25 Sentinel Oncology Limited Derive de2-aminoquinazoline comme des inhibiteurs de p70s6 kinase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136823A1 (fr) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
WO2007144579A1 (fr) * 2006-06-12 2007-12-21 Sentinel Oncology Limited N-oxydes de dérivés de diarylurée et leur utilisation comme inhibiteurs de chk1 pour le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136823A1 (fr) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
WO2007144579A1 (fr) * 2006-06-12 2007-12-21 Sentinel Oncology Limited N-oxydes de dérivés de diarylurée et leur utilisation comme inhibiteurs de chk1 pour le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. CARON ET AL.: "Structure-property relationships in the basicity and lipophilicity of arylalkylamine oxides.", HELVETICA CHIMICA ACTA, vol. 82, 1999, pages 1630 - 1639, XP002488873 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103080089A (zh) * 2010-09-01 2013-05-01 詹森药业有限公司 5-ht2b受体拮抗剂
JP2013536823A (ja) * 2010-09-01 2013-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ２ｂ受容体アンタゴニスト
US8703958B2 (en) 2010-09-01 2014-04-22 Janssen Pharmaceutica, Nv 5-HT2B receptor antagonists
EA020967B1 (ru) * 2010-09-01 2015-03-31 Янссен Фармацевтика Нв Антагонисты рецептора 5-ht
US9139523B2 (en) 2010-09-01 2015-09-22 Janssen Pharmaceutica, Nv 5-HT2B receptor antagonists
CN103080089B (zh) * 2010-09-01 2015-09-23 詹森药业有限公司 5-ht2b受体拮抗剂
WO2012028614A1 (fr) * 2010-09-01 2012-03-08 Janssen Pharmaceutica Nv Antagonistes de récepteur de 5-ht2b
US10159268B2 (en) 2013-02-08 2018-12-25 General Mills, Inc. Reduced sodium food products
US11540539B2 (en) 2013-02-08 2023-01-03 General Mills, Inc. Reduced sodium food products
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
EP3868751A1 (fr) 2015-10-02 2021-08-25 Sentinel Oncology Limited Derive de2-aminoquinazoline comme des inhibiteurs de p70s6 kinase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN110317198A (zh) * 2019-08-13 2019-10-11 信阳师范学院 一种吩噻嗪化合物及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2008139152A1 (fr) Composés pharmaceutiques contenant un n-oxyde
EP3046561B1 (fr) Composés destinés au traitement du cancer de la prostate
US7718674B2 (en) Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
JP6991993B2 (ja) 痛覚過敏を治療する方法
US20150238473A1 (en) Methods and compositions for treating infection
WO2000042852A1 (fr) Composes et procedes
WO2002005819A1 (fr) Composes et procedes
MXPA02006623A (es) 5,10-dihidroacridinas como bloqueadores del canal de sodio.
JP2003516390A (ja) ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
JP2002069004A (ja) 末梢性活性抗痛覚過敏オピエート
US20170172924A1 (en) Tyrosine derivatives and compositions comprising them
JP2003516391A (ja) ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物
ES2445751T3 (es) Agonistas de receptor nicotínico para el tratamiento de enfermedades inflamatorias
WO2004010942A2 (fr) Composes heterocycliques substitues utilises comme modulateurs du recepteur ccr5
KR20190133245A (ko) 지방세포의 처리
US11020391B2 (en) CRMP2 sumoylation inhibitors and uses thereof
ES2529452T3 (es) Compuestos de pirazol como antagonistas de CRTH2
EP1140072A1 (fr) Composes et procedes
EP4071140B1 (fr) Régulateurs cftr et méthodes pour les utiliser
SK7792000A3 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability
JP2009539956A (ja) 医薬品
AU652028B2 (en) Salts of a 4-amino-3-acyl quinoline derivatives
EP3915978A1 (fr) Dérivé de n-benzyl-n-arylsulfonamide, préparation et utilisation associées
KR20030043970A (ko) 2,2-디페닐부탄아미드 유도체 및 이를 함유하는 의약
US6680067B2 (en) Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750536

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08750536

Country of ref document: EP

Kind code of ref document: A1